Venous thromboembolism
Conditions
Interventions
Control group:Rivaroxaban oral tablet initiated at 6 hours postoperatively, 10 mg once daily.
Test group:Rivaroxaban oral tablet initiated at 24 hours postoperatively, 10 mg once daily.
Sponsors
Nanjing Drum Tower Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1.Patients who meet the corresponding surgical indications and undergo total knee revision arthroplasty or total hip revision arthroplasty; 2.Adult patients aged 18 years or older; 3. Patients and their family members fully understand the study content and voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Patients with severe liver or renal dysfunction (estimated glomerular filtration rate eGFR < 30 ml/min/1.73 m²); 2.Use of other anticoagulant or antiplatelet drugs within the past 1 month that cannot be discontinued due to medical conditions; 3.Cognitive impairment, psychiatric disorders, or communication difficulties that preclude cooperation with study assessments; 4.Known hypersensitivity to rivaroxaban or other direct oral anticoagulants (DOACs); 5.History of bleeding disorders or conditions affecting coagulation function, including but not limited to hemophilia, thrombocytopenia (platelet count < 100×10?/L), active gastrointestinal ulcer bleeding, history of intracranial hemorrhage within the past 3 months, or history of major trauma or major surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Thrombosis incidence rate;Postoperative drainage volume; | — |
Countries
China
Contacts
Public Contactxuruijuan
Nanjing Drum Tower Hospital
Outcome results
None listed